Research Reports

Summary

Azitra, Inc. announced financial results for the full year ended December 31, 2025, reporting a net loss of $11.0 million compared to $9.0 million in the prior year. The company ended the period with $2.1 million in cash and equivalents, while highlighting progress in its ATR-12, ATR-04, and ATR-01 clinical programs.

Key takeaways

Reported a net loss of $11.0 million for the year ended December 31, 2025, compared to a net loss of $9.0 million for the year ended December 31, 2024.
Cash and cash equivalents totaled $2.1 million as of December 31, 2025, down from $4.6 million as of December 31, 2024.
Research and Development expenses were $4.8 million for 2025, compared to $4.7 million for 2024.
Completed financings of $8.5 million through private placements, follow-on financings, and utilization of an equity line of credit.
Announced topline data for the Phase 1b trial of ATR-12 in Netherton Syndrome is anticipated in H2 2026.
Dosed the first patient in the Phase 1/2 trial for ATR-04 targeting oncology patients with EGFRi-associated rash in Q3 2025.